AEZS - Aeterna Zentaris to regain full rights to Macrilen oral test from Novo Nordisk

• Aeterna Zentaris ( NASDAQ: AEZS ) on Monday said it would regain the U.S. and Canadian rights for Macrilen, an oral test to detect adult growth hormone deficiency, from Danish pharmaceutical company Novo Nordisk ( NVO ).
• The company said it would get the rights back after NVO decided to terminate the amended development and commercialization licensing agreement between the two parties.
• NVO will have a 270-day notice period in which it will continue to sell and promote Macrilen in the U.S.
• "In light of Novo Nordisk’s decision, Aeterna plans to engage in robust business development efforts to identify and secure a new development and commercialization partner," AEZS said in a statement .
• AEZS stock -1.8% to $5 in morning trading.

For further details see: